M. Kulyk & Associates LLC Has $274,000 Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

M. Kulyk & Associates LLC grew its position in shares of Novo Nordisk A/S (NYSE:NVO) by 3.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,182 shares of the company’s stock after purchasing an additional 119 shares during the quarter. M. Kulyk & Associates LLC’s holdings in Novo Nordisk A/S were worth $274,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the company. Capital Performance Advisors LLP bought a new position in shares of Novo Nordisk A/S during the third quarter worth about $42,000. Verdence Capital Advisors LLC raised its position in shares of Novo Nordisk A/S by 18.9% during the third quarter. Verdence Capital Advisors LLC now owns 42,977 shares of the company’s stock worth $5,117,000 after acquiring an additional 6,821 shares during the last quarter. Assetmark Inc. raised its position in shares of Novo Nordisk A/S by 5.1% during the third quarter. Assetmark Inc. now owns 441,882 shares of the company’s stock worth $52,615,000 after acquiring an additional 21,553 shares during the last quarter. Wealth Quarterback LLC bought a new position in shares of Novo Nordisk A/S during the third quarter worth about $856,000. Finally, Bridges Investment Management Inc. raised its position in shares of Novo Nordisk A/S by 2.0% during the third quarter. Bridges Investment Management Inc. now owns 7,700 shares of the company’s stock worth $917,000 after acquiring an additional 150 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Stifel Nicolaus downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Morgan Stanley began coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Finally, BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and an average target price of $145.25.

Novo Nordisk A/S Trading Down 1.0 %

Shares of Novo Nordisk A/S stock opened at $87.19 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. Novo Nordisk A/S has a 52 week low of $77.82 and a 52 week high of $148.15. The stock has a 50 day moving average price of $84.91 and a two-hundred day moving average price of $105.07. The stock has a market capitalization of $391.25 billion, a PE ratio of 26.50, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be paid a $0.7874 dividend. This represents a yield of 1.2%. The ex-dividend date is Monday, March 31st. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio (DPR) is 47.72%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.